MYCN and metastatic neoplasm: Established clinico-molecular risk-features (age at diagnosis, metastatic disease, histological variants, extent of surgical resection and amplification of MYCN) were equivalently distributed between both groups (Fig. 2a, Supplementary Fig. S6a, online resource).